论文部分内容阅读
光清除法是最近由美国食物和药品管理局批准治疗皮肤T细胞淋巴瘤的1种新技术。此疗法系将口服可用光激活的细胞毒药物和白细胞单采结合起来,并将白细胞暴露于体外长波紫外光(UVA)下。这个过程需要使用Therakos公司、Johnson and Johnson分公司制造的“UVAR”仪器。皮肤T细胞淋巴瘤皮肤T细胞淋巴瘤包括长期以来以其它名称定名的各种不同的皮肤病,如Sezary综合症、蕈样霉菌病、网状细胞肉瘤和大多数成人T细胞白血病。此病通常是致命的,确诊后的存活时间约为3-10年。
Light scavenging is a new technology recently approved by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. This therapy combines orally available photoactivatable cytotoxic drugs with leukocyte apheresis and exposes leukocytes to long-wave ultraviolet light (UVA) in vitro. This process requires the use of “UVAR” instruments manufactured by Therakos, Johnson and Johnson offices. Cutaneous T-cell lymphoma Cutaneous T-cell lymphoma encompasses a wide variety of different skin diseases, such as Sezary’s syndrome, mycosis fungoides, reticular cell sarcoma, and most adult T-cell leukemias, which have long been named by other names. The disease is usually fatal, after diagnosis of survival time of about 3-10 years.